Flexion Therapeutics (NASDAQ: FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.
Zilretta™ (FX006), Flexion’s lead investigational drug candidate, was developed with the goal of enhancing the clinical effect of intra-articular corticosteroid treatment. Zilretta is an extended-release formulation of triamcinolone acetonide designed to prolong local residence following intra-articular injection. Zilretta is formulated using proprietary microsphere technology combining triamcinolone acetonide with a poly lactic-co-glycolic acid (PLGA) matrix. In 2015, Zilretta received Fast Track Designation from the FDA. An NDA (New Drug Application) for Zilretta (FX006) was submitted to the FDA in December 2016.
Flexion is based in Burlington, Massachusetts.